Drugs / Trivalent Influenza Virus Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01579916 | May → Nov 2012 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 4 | NCT00677820 | Jun → Jul 2008 | influenza | MedImmune LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2010-10-22 | AstraZeneca | Regulatory European regulator backs nasal spray vaccine FLUENZ for the prevention of seasonal influenza in children astrazeneca.com ↗
AstraZeneca announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the marketing authorisation application for FLUENZ Influenza Vaccine (Live attenuated, nasal), its nasally administered live attenuated influenza vaccine (LAIV) for prevention of seasonal influenza. |
| 2009-01-06 | AstraZeneca | Regulatory MedImmune Submits Marketing Authorisation Application in European Union for Intranasal Vaccine to Prevent Seasonal Influenza astrazeneca.com ↗
MedImmune, the global biologics unit of AstraZeneca, announced today that it has submitted a Marketing Authorisation Application (MAA) for its nasal spray live attenuated influenza vaccine (LAIV), which is now being reviewed by the European Medicines Agency (EMEA). |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Influenza Virus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01579916 ↗ |
| Known as | FluMist | “This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza...” NCT01579916 ↗1“not previously contained in the trivalent intranasal FluMist vaccine” NCT00677820 ↗ |
| Modality | Vaccine | “Trivalent influenza virus vaccine” NCT00677820 ↗ |
| Route | Intranasal | “by intranasal spray” NCT00677820 ↗ |